Less is more, but are we doing enough?

Regulation of nanotechnology: Are we doing enough?

the Nanotechnology Task Force of the Food and Drug Administration (FDA) of the United States released a report which addressed the regulatory challenges presented by products that use nanotechnology (FDA 2007). Since most of these potential products involve nanomaterial interactions with biological tissues, this report directly speaks to the fi eld of nanomedicine. A general fi nding of the rep...

Severe sepsis management are we doing enough?

For the first time in medical history, a drug has been shown to reduce the mortality associated with sepsis, the leading cause of death in many ICUs. Optimal use by appropriate selection of patients and early recognition of sepsis could save thousands of lives. Nurses play a major role in recognizing severe sepsis. By using the concepts introduced here, nurses can play a direct role in saving t...

Are We Doing Enough for Our Field ?

Correspondents Argentina: O. Civitaresse, La Plata; Australia: A. W. Thomas, Adelaide; Austria: H. Oberhummer, Vienna; Belgium: M. Huyse, Leuven; Brasil: M. Hussein, Sao Paulo; Bulgaria: D. Balabanski, Sofia; Canada: J.-M. Poutissou, TRIUMF; K. Sharma, Manitoba; J. Simpson, Guelph; China: W. Zhan, Lanzhou; Croatia: R. Caplar, Zagreb; Czech Republic: J. Kvasil, Prague; Slovak Republic: P. Povine...

Coronary thrombosis in diabetes: Are we doing enough?

Exercise-Induced Bronchoconstriction in College Athletes: Are We Doing Enough?

More Americans than ever before have asthma, and although the disease can be managed with proper trigger prevention and treatment, there are still a significant number of deaths. The Centers for Disease Control and Prevention report that 1 in 14 people have asthma, with 3,651 deaths reported in 2014 at an annual cost of $56 billion.1,2 Adults are nearly 7 times more likely to die from asthma th...